Selecting patients for TRISENOX therapy
TRISENOX
® (arsenic trioxide) injection is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.
The first consideration for patient selection is determining where your patient is in the APL treatment sequence. If your APL patient has relapsed after initial therapy, or if he/she did not respond to initial therapy, TRISENOX may be an appropriate option. TRISENOX provides the opportunity for complete remission and improved survival in patients with refractory/relapsed APL.
1,2 According to the National Comprehensive Cancer Network (NCCN) guidelines for oncology, arsenic trioxide is the standard of care for relapsed or refractory APL patients.
3
Please visit www.NCCN.org to review clinical practice guidelines in oncology.
Note: The APL management algorithm is contained within the clinical practice guidelines for Acute Myeloid Leukemia (AML).
1. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
2. Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia — v.2.2007.